en
svPress releases
Regulatory press release 2020-05-29
Xspray Pharma initiates pivotal registration studies with HyNap-Dasa for the market approval application in the United States
Regulatory press release 2020-05-14
Bulletin from the annual general meeting of Xspray Pharma AB (publ)
Regulatory press release 2020-04-15
Xspray Pharma provides an update on how the Covid-19 pandemic affects the company’s planned clinical studies
Regulatory press release 2020-04-14
XSpray: Notice of annual general meeting of Xspray Pharma AB (publ)
Regulatory press release 2020-03-18
Xspray Pharma approved for listing on Nasdaq Stockholm
Regulatory press release 2020-03-17
Xspray receives notification of manufacturing approval and provides update on clinical studies
Regulatory press release 2020-02-11
Stability studies initiated with Xspray’s HyNap-Dasa tablets
Regulatory press release 2019-12-05
Xspray Pharma has carried out a directed share issue raising gross proceeds of approximately SEK 122 million
Regulatory press release 2019-12-05
Xspray Pharma contemplates a directed share issue
Regulatory press release 2019-10-31